1336963-95-1

Basic information

• Product Name: 6-bromo-7-fluoroisatin
• Synonyms: 6-bromo-7-fluoroisatin;6-bromo-7-fluoroindoline-2,3-dione;6-bromo-7-fluoro-2,3-dihydro-1H-indole-2,3-dione;6-Bromo-7-fluoro-1H-indole-2,3-dione
• CAS NO: 1336963-95-1
• Molecular Formula: C₈H₃BrFNO₂
• Molecular Weight: 244.0173232
• Mol File: 1336963-95-1.mol

Chemical Properties

• Appearance: /
• Density: 1.907±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 7.42±0.20(Predicted)
• CAS DataBase Reference: 6-bromo-7-fluoroisatin(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-7-fluoroisatin(1336963-95-1)
• EPA Substance Registry System: 6-bromo-7-fluoroisatin(1336963-95-1)

Safety Data

• Hazardous Substances Data: 1336963-95-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-bromo-7-fluoroisatin is used as a heterocyclic reagent for the synthesis of electrophiles that are capable of targeting K-Ras oncogene. This targeting is crucial in the treatment of various types of cancer, as the K-Ras oncogene is often mutated in several malignancies, leading to uncontrolled cell growth and tumor formation.
Used in Chemical Synthesis:
6-bromo-7-fluoroisatin is also utilized as a key intermediate in the synthesis of various chemical compounds, particularly those with potential applications in the pharmaceutical industry. Its unique structure allows for further functionalization and modification, enabling the development of new drugs and therapeutic agents.

Upstream product

• 58534-95-5 3-bromo-2-fluorobenzenamine 
• 302-17-0 chloral hydrate 

Downstream Products

• 1698027-17-6 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid 
• 1698024-73-5 1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one 

Relevant articles and documents

Fused pyridone compounds as kinase inhibitors

The invention discloses a fused pyridone compound serving as a kinase inhibitor, and particularly discloses a compound represented by formula (I). The optical isomer and pharmaceutically acceptable salt thereof as well and as application of the compound as KRAS inhibitor.

(AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides (aza)indazolyl-aryl sulfonamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting GCN2 activity.

Quinazoline compound and application thereof in medicine (by machine translation)

The invention relates to a quinazoline compound (shown in the formula I) and a medicinal salt thereof, which can be used for treating cancer. The invention also relates to a preparation method and a pharmaceutical composition containing the compounds. (by machine translation)

CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.

2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, G1, G2, L1, L2, m1, m2, n, X and E are as defined herein, and wherein at least one of R3a, R3b, R4a or R4b is not H. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS

The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.

INHIBITORS OF KRAS G12C MUTANT PROTEINS

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein A, B R1, R2a, R2b, R3a, R3b, R4a, R4b, G1, G2, m1, m2, L1, L2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

METHODS AND COMPOSITIONS FOR INHIBITION OF RAS

Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer.

SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, B, G1, G2, L1, L2, m1, m2, n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Containing an electron-withdrawing group heterobasidion indigoes compound and its preparation and use

The invention discloses an isoindigo compound containing electron-withdrawing groups, and preparation and an application thereof. Isoindigo compound monomers with electron-withdrawing substituents are polymerized with other aromatic compound monomers to form the polymer; because an isoindigo skeleton contains the electron-withdrawing substituents, the isoindigo compound can effectively reduce the energy level of a lowest unoccupied orbit of the polymer, thereby greatly improving the mobility of electrons in the polymer; the isoindigo compound can be used as an n-type material (which can transport electrons) or a bipolar transport material (which can transport both holes and electrons) applied to an organic field effect transistor, an organic solar cell, an organic light-emitting diodes and other photoelectric devices.